Member Info for JimiHendrix

Website redesigns are a lot of work – certainly not something a company would embark on if they were winding up.

There’s a new 3rd test the company mentioned in the webinar last month. I forget the details, but recall something expected later this year. It’s not a huge market like CYP2C19 but still it’s extra revenue.

The company has said that they’re balancing updating the market with not giving too much away to competitors. My feeling is good things are about to happen, but the wait is very hard going, especially with the share price getting dragged down.

There’s been persistent £3k and £5k sells at various prices down which suggests somebody with a large holding selling down chunks and then regular 1 million buys mopping them up.

With EBITDA positive only ~6 months away, I don’t believe they should find it difficult to get the bridging funding that they’ll probably need in a couple of months.

As long as they’re able to show a potential investor how/when they are going to be EBITDA+ then loaning the money on good terms would be a no brainer, when that revenue is received the share price will be multiples of where it is now.

Sorry posting again in one go so it’s easier to read…

All HASU's will need to use the Genedrive POC, plus other units whose lab can't reliable meet the less than 24hr TAT.

Lab CYP2C19 genotyping takes 1–14  days (average 6 days)—far longer than the therapeutic timelines in the 2023 National Stroke Guideline, which calls for dual antiplatelet therapy within 24 h of symptom onset.

Who needs point‑of‑care (POC):

• Hyper‑acute stroke units (HASUs): work to a door‑to‑needle goal of less than 1 h, so only a bedside test such as Genedrive’s ~70 min cartridge can influence the first dose.

• Acute Stroke Units (ASUs) and network “spoke” hospitals: must still start clopidogrel less than 24 h; if their regional lab cannot guarantee that turnaround they will also need POC to avoid treatment delays or repeat admissions.

• Integrated Stroke Delivery Networks (ISDNs): commissioners are expected to mandate POC at any site whose lab pathway fails audit against the 24‑hour KPI.

With DG59 now moving through NHS England’s national‑commissioning gateway, centrally funded cartridges will make POC clinically necessary and budget‑neutral. Early adopters will hit quality metrics first, while centres sticking with slow lab workflows face retesting costs and potential KPI penalties.

Strange, it didn't like my symbols, I'll try again...

Here's the rest of my post :) ...

Who needs point‑of‑care (POC):

• Hyper‑acute stroke units (HASUs): work to a door‑to‑needle goal of less than 1 h, so only a bedside test such as Genedrive’s ~70 min cartridge can influence the first dose.

• Acute Stroke Units (ASUs) and network “spoke” hospitals: must still start clopidogrel less than 24 h; if their regional lab cannot guarantee that turnaround they will also need POC to avoid treatment delays or repeat admissions.

• Integrated Stroke Delivery Networks (ISDNs): commissioners are expected to mandate POC at any site whose lab pathway fails audit against the 24‑hour KPI.

With DG59 now moving through NHS England’s national‑commissioning gateway, centrally funded cartridges will make POC clinically necessary and budget‑neutral. Early adopters will hit quality metrics first, while centres sticking with slow lab workflows face retesting costs and potential KPI penalties.

Here's the rest of my post :) ...

Who needs point‑of‑care (POC):

• Hyper‑acute stroke units (HASUs): work to a door‑to‑needle goal of

All HASU's will need to use the Genedrive POC, plus other units whose lab can't reliable meet the ≤ 24hr TAT.

Lab CYP2C19 genotyping takes 1–14  days (average 6 days)—far longer than the therapeutic timelines in the 2023 National Stroke Guideline, which calls for dual antiplatelet therapy within 24 h of symptom onset.

Who needs point‑of‑care (POC):

• Hyper‑acute stroke units (HASUs): work to a door‑to‑needle goal of

This test has only had the UKCA mark for 2 years and NICE recommendation a year ago.

Those sites are mainly sites taking part in the PALOH UK pilot, which concluded in early May. National commissioning is highly anticipated in the next couple of weeks (any day now!).

Which will rapidly move the company to EBITDA positive by June 30th.

Genedrive’s CYP2C19 POC test is currently being used in the following 9 hospitals (soon to be many more hopefully):

1. Salford Royal Hospital

Northern Care Alliance, Greater Manchester

Hyper-acute Stroke Centre (HASU) & ACS pilot

2. Peterborough City Hospital

North West Anglia FT

Hyper- & acute stroke units (routine)

3. Manchester Royal Infirmary

Manchester University NFT (MFT)

Stroke unit (implementation lead)

4. Wythenshawe Hospital

Manchester University NFT

Stroke/PCI service (regional roll-out)

5. North Manchester General Hospital

MFT

Stroke ward (Greater Manchester network)

6. Royal Oldham Hospital

Northern Care Alliance

Satellite stroke centre (linked to Salford)

7. Fairfield General Hospital

Northern Care Alliance

Stroke rehabilitation & secondary prevention

8. Royal Bolton Hospital

Bolton NHS FT, GM

Acute stroke rota (pilot)

9

Stepping Hill Hospital

Stockport NHS FT, GM

Hyper-acute stroke/ED bays (pilot)

Found something positive…

UK insurer Bupa launches a £300 Medication Check DNA kit (saliva, mail-in, 111 drugs). CYP2C19 variants are explicitly on the panel—clopidogrel guidance features heavily in the promo.

Not a bedside cartridge, but it puts CYP2C19 genotyping into everyday retail healthcare and will reach 3 million+ covered employees this autumn. • Early-adopter signal for broader consumer/primary-care uptake, which could spur true POC demand in GP surgeries.

This benefits Genedrive as their NHS-list price is ~£100 per test, so the cost-effectiveness gap widens. Insurer endorsement should accelerate tariff codes and pave the way for wider NHS commissioning, strengthening Genedrive’s NICE recommendation.

Partnering play: Bupa’s private GP hubs or high-street health centres are natural sites for a 70-minute cartridge test—Genedrive could license devices or offer “while-you-wait” confirmatory testing.

Well spotted John, that’s 11 NICUs live now, 3 more to come as part of group 2.

It all comes down to cash at the moment and whether the guide and toolkit arrive before they get desperate. As currently I think they’re going to need a bridging loan, facility or small placing sorted by October.

If the toolkit lands soon then hopefully they’ll do a small raise later at a much higher price. If it slips they might have no choice but to lower the nominal 1.5p price... Apparently though they can announce a conditional placing at a price below nominal, contingent on the passing of a GM resolution to reduce the nominal value, the general meeting would come 14-28 days later.

The sooner the toolkit lands the sooner they can start taking orders from the stroke centres. Which might along with other things (Scotland) extend the runway a month or so.

Promising but I doubt there’s much market for a rapid test in the antidepressant prescription world, I’m sure there are some niche circumstances or settings but generally labs can probably handle those imo.

A general meeting would be called giving shareholders a couple of weeks notice and a circular released. By that time though the guide could be out and share price higher so am doubtful they’d get shareholders vote. A loan and/or maybe a smaller placing later above 1.5 would be a much better option.

I believe they have funding until October (later if they get some up front payments for CYP2C19 rollout and Scotland or other sales not disclosed).

My hope is that the company doesn’t panic or is pressurised to lower the nominal value to be sure they can raise funds when they need to. Instead I would expect them to wait until after the implementation guide and toolkit is published when the share price is likely much higher (crucially above 1.5) before raising (without messing with share reorganisation).

Alternatively I think with clear revenue visibility now on the horizon there’s a good chance they’ll get some kind of loan facility or CLN to provide them £1-2m which should tide them over until meaningful revenue is received.

Roger, cardiac arrest commissioning will come later imo, after the 12 month trial.

And a third worked 1000000 buy order showing up after hours.

I don’t think Peel are holding any significant number of shares, surely there would have been a TR1 or it would show on the share register.

Refreshing to see that they are not recent, in fact 2 CEOs ago. I sense things are far improved now.

Come on NHSE let’s have the implementation guide.